Autologous CD19-targeted CAR-T cells were approved for clinical use in patients with B-acute lymphoblastic leukemia (ALL) or diffuse large B cell lymphoma (DLBCL) in 2017 [116,117,118,119,120,121,122,123]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.